Observational studyCritical care (London, England)2026

Evaluating plasma ferritin and suPAR as treatable traits for critically ill patients with COVID-19 treated with anakinra: an exploratory analysis of the immune modulation domain of the REMAP-CAP randomised clinical trial.

Andrew J Boyle et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.